We differentiate ourselves by providing our clients and partners with the confidence of a successful antibody discovery program targeting GPCRs.

This critical class of drug targets is implicated in multiple major diseases, and we deliver innovative solutions to unlock their therapeutic potential.

Our RedQueen platform designs breakthrough biologics against complex protein receptors by uniting the principles of evolutionary computation with physics-based modeling and cutting-edge AI.

Through digital directed evolution, we replicate the natural process by which the immune system develops new antibodies, uncovering solutions that conventional technologies cannot reach.

We apply the principles of evolution to explore the vast space of antibody variants.

Unlike conventional generative AI, which often fails to predict effective new antibodies, our approach delivers accurate and reliable insights into antibody–antigen interactions.

What is Discovery Evolution?

Discovery Evolution is a deep-tech biotechnology company specializing in the digital discovery of novel biologics. We bridge the gap between computational modeling and therapeutic reality by identifying candidates for „undruggable“ targets that traditional lab-intensive methods cannot reach.

How does our platform accelerate drug discovery?

Our proprietary platform integrates physics-based modeling with digital directed evolution. It emulates the process of adaptive immunity in a digital environment. This results in higher hit rates, reduced downstream clinical risk, and significantly faster timelines for antibody discovery.

What specific challenges does Discovery Evolution solve for Biopharma partners?

We solve the „undruggable“ bottleneck, specifically targeting complex transmembrane protein receptors like GPCRs (G-Protein Coupled Receptors). These are critical for the treatment of many consequential diseases including cancer, metabolic, cardiovascular and neurological disorders – but they are also notoriously difficult to target using traditional screening methods. We move early discovery from the lab bench to the digital world, removing the limitations of physical assays.